US Breast Cancer Drug Market 2019-2025 Opportunity: $ 20 Billion

DUBLIN–(BUSINESS WIRE)–The “US
Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight
2025” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

“US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline
Insight 2025” Report Highlights:

• US Breast Cancer Drug Market Opportunity: US$ 20 Billion
• US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class
  & Patient Segment
• US Breast Cancer Marketed Drugs: 42 Drugs
• US Breast Cancer Drug Clinical Pipeline: 317 Drugs
• Dosage & Pricing Insight for Preventive & Treatment Drugs
• US Breast Cancer Drug Market Dynamics

Breast cancer is the most commonly diagnosed cancer in American women.
Breast cancer occurring in a woman under 40 is not a typical condition
anymore. Changing lifestyles with numerous other factors like early
menarche, late age at first childbirth, late menopause and prolonged
exposure to endogenous oestrogens are surging the breast cancer drug
market at a high rate. Also, short breast-feeding timeframe, rising of
obesity in women after menopause, increasing rate of alcohol consumption
in women, rising use of hormone replacement therapy (HRT) and oral birth
control pills which causes increased levels of oestrogen are boosting
the breast cancer drug market to its peak.

Various breast cancer therapeutics have come into existence like hormone
drugs, chemotherapy drugs and targeted drugs. With advancements in drug
delivery systems, target-specific therapies are prevailing. Also,
ER-positive drugs for breast cancer are being introduced to the market.
Drugs approved for the prevention of breast cancer like Raloxifene
Hydrochloride, Elvista, etc. and drugs approved for the treatment of
breast cancer like Abemaciclib, Abraxane, Xeloda, Taxol, Methotrexate,
etc. have been mentioned in detail with indication, dosing and pricing
in our report on US Breast Cancer Drug Market.

US breast cancer drug market has high potency of growth with 42 drugs
being commercially available and more than 300 of them being in the
clinical pipeline. It is definitive that the market will grow due to the
increase in the prevalence of breast cancer and a large geriatric
population. Also, it has become a priority for researches and everyone
linked to the healthcare system to find a cure for the second most
commonly occurring disease. Even if the growth is slow it will increase
exponentially in the near future.

Inaccessibility of the absolute treatment has given a wide scope of
stage for the improvement of the US breast cancer drug market.
Pharmaceutical companies are now concentrating on the improvement of new
products which will be cost effective and will also have the fewest side
effects. Different organizations are also engaged with the advancement
of specific types of molecules and novel therapies. These organizations
have adopted the methodologies of the acquisitions, and furthermore
propelling of the new products so as to endeavor in this huge and
competitive market. Additionally, competition among new market players
is likewise expected to expedite the growth for breast cancer drugs
market in the near future.

Key Topics Covered:

1. US – Cancer Incidence & Prevalence

2. US Breast Cancer Market Landscape

2.1 Incidence & Prevalence

2.2 Diagnosis of Breast Cancer

3. US Breast Cancer Drug Market

3.1 Overview US Breast Cancer Drug Market

3.2 Diagnosis & Screening Market Scenario

3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class,
Company, Patient Segment)

4. Forward-Looking Developments in Breast Cancer Drug Market

4.1 ER Positive Breast Cancer

4.1.1 CDK4/6 Inhibitors

4.1.2 PI3K Inhibitors

4.1.3 Crizotinib for Lobular Breast Cancer

4.2 HER2-Positive Breast Cancer

4.2.1 Palbociclib & Herceptin (Spain)

4.2.2 Tecentriq – FDA Approval for Breast Cancer

4.3 Triple Negative Breast Cancer

4.3.1 Atezolizumab & Nab-Paclitaxel

4.3.2 Sacituzumab Govitecan

4.3.3 Carboplatin & Docetaxel

5. US – Dosage & Pricing Insight for Drugs Approved for the
Prevention of Breast Cancer

5.1 Raloxifene Hydrochloride

5.2 Elvista

5.3 Tamoxifen Citrate

6. US – Dosage & Pricing Insight for Drugs Approved for the
Treatment of Breast Cancer

6.1 Abemaciclib

6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

6.3 Ado-Trastuzumab Emtansine

6.4 Afinitor (Everolimus)

6.5 Anastrozole

6.6 Aromasin (Exemestane)

6.7 Xeloda (Capecitabine)

6.8 Docetaxel (Docetaxel Anhydrous)

6.9 Doxorubicin Hydrochloride

6.10 Ellence (Epirubicin Hydrochloride)

6.11 Fluorouracil

6.12 Taxol (Paclitaxel)

6.13 Methotrexate

6.14 Cyclophosphamide

7. US Breast Cancer Drug Market Dynamics

7.1 Market Drivers

7.1.1 Increasing Incidence of Breast Cancer

7.1.2 Research & Development for Novel Drugs

7.1.3 Increase in Healthcare Expenditure & Funding

7.1.4 Increasing Breast Cancer Screening Programs

7.1.5 Rising Consumption of Tobacco & Alcohol

7.2 US Breast Cancer Drug Market Challenges

7.2.1 Pricing Pressure Experienced by the Innovators

7.2.2 High Cost associated with Drug Development & Clinical Trials

7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US – Breast Cancer Drug Market Forecast

8.1 Future Potential of US Breast Cancer Drug Market

8.2 Opportunities for Forthcoming Drug Classes

9. US – Breast Cancer Drug Clinical Pipeline by Company & Phase

9.1 Research

9.2 Preclinical

9.3 Clinical

9.4 Phase-I

9.5 Phase-I/II

9.6 Phase-II

9.7 Phase-II/III

9.8 Phase-III

9.9 Preregistration

9.10 Registered

10. US – Marketed Breast Cancer Drug Clinical Insight by Company

10.1 Afinitor

10.2 LYNPARZA

10.3 Abraxane

10.4 Verzenio

10.5 Kisqali

10.6 Lymphoseek

10.7 Kadcyla

10.8 Ibrance

10.9 Nerlynx

10.10 Soltamox

10.11 Tykerb

10.12 Zoladex

10.13 Omnitarg, Perjeta

10.14 Halaven

10.15 Taxotere

10.16 Other( 27 Drugs Profiles)

11. Competitive Landscape

11.1 Agilent Technologies

11.2 AstraZeneca

11.3 Bayer HealthCare Pharmaceuticals

11.4 Bristol-Myers Squibb

11.5 Eisai Co Ltd

11.6 Eli Lilly

11.7 Novartis

11.8 Onyx Pharmaceuticals

11.9 Orion

11.10 Perrigo

11.11 Pfizer

11.12 Roche

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ejpi

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health, Breast
Cancer Drugs